“Our results confirm that XSTEM, which consists of integrin α10β1-selected stem cells, has the properties required to repair damaged joint cartilage and is a unique product in the field. By labeling the stem cells, we have been able to show that the injected stem cells migrate to the damaged cartilage, develop into cartilage cells and directly contribute to producing new cartilage tissue. This demonstrates that XSTEM has excellent potential to be a so-called DMOAD (Disease Modifying Osteoarthritis Drug), a treatment that can prevent further degradation of the cartilage in osteoarthritis patients and also be able to regenerate the cartilage and improve joint function. There is currently no DMOAD on the market”, says Xintela's CEO Evy Lundgren-Åkerlund.

Xintela has previously shown that the company's integrin α10β1-selected mesenchymal stem cells have a therapeutic effect on cartilage and bone in an osteoarthritis model in horses. In order to increase understanding of XSTEM's mechanisms of action, Xintela has performed additional preclinical studies in collaboration with the University of Copenhagen. Xintela has in a previous press release (May 18, 2021) informed about preliminary results from the study. Clinical studies with XSTEM has recently been initiated in Australia for the treatment of knee osteoarthritis and the company plan to start clinical studies in patients with difficult-to-heal leg ulcers after the summer.